UK Markets closed

Chr. Hansen Holding A/S (0MR6.L)

YHD - YHD Delayed price. Currency in USD
Add to watchlist
- (-)
At close: 06:07PM EDT
Full screen
Previous closeN/A
YTD returnN/A
Expense ratio (net)N/A
CategoryN/A
Last cap gainN/A
Morningstar ratingN/A
Morningstar risk ratingN/A
Sustainability ratingN/A
Net assetsN/A
Beta (5Y monthly)N/A
YieldN/A
5y average returnN/A
Holdings turnoverN/A
Last dividendN/A
Average for categoryN/A
Inception dateN/A
  • Globe Newswire

    Lillie Li Valeur steps down from the Board of Directors

    Company announcement no. 04/2022 April 25, 2022 Please see attachment. For further information, please contact:Anders Mohr Christensen, Vice President Group Strategy & Investor Relations, Tel: +45 2515 2364Annika Stern, Senior Investor Relations Manager, Tel: +45 2399 2382Sanne Seyer-Hansen, Head of Media Relations, Tel: +45 6038 6207 About Chr. HansenChr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical an

  • Globe Newswire

    Chr. Hansen Holding A/S Interim Report Q2 2021/22

    Company announcement no. 03/2022 April 6, 2022 Strong Q2 growth in a challenging environment Statement by CEO Mauricio Graber: “In a challenging environment, Chr. Hansen continued its strong growth trajectory, delivering 14% organic growth in the second quarter. Growth in Health & Nutrition further accelerated, supported by Human Health, while Food Cultures & Enzymes showed solid growth, mainly driven by its core segments and developed markets. In the second quarter, the EBIT margin b.s.i. incre

  • Globe Newswire

    Chr. Hansen Holding A/S Interim Report Q1 2021/22

    January 13, 2022 Company announcement no. 1 Solid start to the year Statement by CEO Mauricio Graber: “The encouraging start to the year with organic growth of 9% and progress across all business areas and strategic initiatives underlines the strength of our 2025 strategy differentiating us as a bioscience company focused on microbial and fermentation technology platforms. Food Cultures & Enzymes continued its strong momentum in the first quarter, while Health & Nutrition delivered a strong reb